Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 4Phase 1 3Phase 1/2 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 1Endocrine 1

Conditions

Cushing Syndrome 2Prostatic Neoplasms 1Pathologic Processes 1Neoplasms 1Hypertension 1Hyperglycemia 1Glucose Intolerance 1Endocrine System Diseases 1Diabetes Mellitus, Type 2 1Adrenocortical Hyperfunction 1Adrenocortical Carcinoma 1Adrenal Gland Diseases 1Adrenal Cortex Neoplasms 1ACTH Syndrome, Ectopic 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × relacorilant × Clear all
NCT03674814 2026-03-31

Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

University of Chicago

Phase 1 Completed
42 enrolled
Genitourinary

Prostatic Neoplasms

NCT04373265 2024-02-23

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

Corcept Therapeutics

Phase 1 Completed
15 enrolled
Endocrine

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Adrenal Gland Diseases, Adrenocortical Hyperfunction, Cushing Syndrome, Diabetes Mellitus, Type 2, Endocrine System Diseases, Hyperglycemia, Hypertension, Pathologic Processes, Glucose Intolerance, Adrenocortical Carcinoma

NCT05347979 2023-02-09

Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

Corcept Therapeutics

Phase 1 Completed
30 enrolled

Cushing Syndrome, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡